March 2011. Volume 7. Number 1

Vaccination with PCV13 is likely to be cost-saving in USA

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Rubin JL, McGarry LJ, Strutton DR, Klugman KP, Pelton SI, Gilmore KE et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine. 2010;28:7634-43.
Reviewers: Aizpurua Galdeano P1, García Vera C2.
1ABS 7 La Salut Badalona. Badalona. España.
2CS Sagasta-Ruiseñores. Zaragoza. España.
Correspondence: Pilar Aizpurua Galdeano. Email: 19353pag@gmail.com
Reception date: 17/01/2011
Acceptance date: 25/01/2011
Publication date: 27/01/2011

Abstract

Authors’ conclusions: vaccination with PCV13 is likely to be a cost-effective or cost-saving health-care intervention under all scenarios examined, even as a serotype catch-up program.

Reviewers’ commentary: this study forecasts that vaccination with PCV13 would  be currently cost-effective and cost-saving in USA. With similar background, PCV7 decreased its cost-effectiveness because of increases of disease caused by non-vaccine serotypes. Further studies with real data after the implementation of vaccination with PCV13 are needed, not only in USA but also in other countries with different epidemiological situations and vaccination programs.

How to cite this article

Aizpurua Galdeano P, García Vera C. La vacuna neumocócica 13-valente parece coste efectiva en Estados Unidos. Evid Pediatr. 2011;7:12.

AVC | Critically appraised articles

Rubin JL, McGarry LJ, Strutton DR, Klugman KP, Pelton SI, Gilmore KE et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine. 2010;28:7634-43.
Reviewers: Aizpurua Galdeano P1, García Vera C2.
1ABS 7 La Salut Badalona. Badalona. España.
2CS Sagasta-Ruiseñores. Zaragoza. España.
Correspondence: Pilar Aizpurua Galdeano. Email: 19353pag@gmail.com
Reception date: 17/01/2011
Acceptance date: 25/01/2011
Publication date: 27/01/2011

How to cite this article

Aizpurua Galdeano P, García Vera C. La vacuna neumocócica 13-valente parece coste efectiva en Estados Unidos. Evid Pediatr. 2011;7:12.

References

  1. Centers for Disease Control and Prevention. Invasive Pneumococcal Disease in Young Children Before Licensure of 13-Valent Pneumococcal Conjugate VaccineUnited States, 2007. MMWR. 2010;59:253-7.
  2. Fernández Oropesa C. Las múltiples caras del conflicto de intereses y sus implicaciones en la práctica clínica. Evid Pediatr. 2010;6:71.
  3. Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, van den Dobbelsteen G et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ. 2010;340:c2509.
27/01/2011

Linked Comment